Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I Contacted Cliff

Which cup is the pea under ?

Seems pretty express and explicit to me..

..."Pursuant to the Program Agreement, PDS engaged Alliacense to negotiate MMP portfolio licenses and to pursue claims against violators of the MMP portfolio on behalf of PDS, TPL, and the Company."...

From the PTSC quarterly period ended August 31, 2012

Investment in Affiliated Company

"On July 11, 2012, we entered into a Licensing Program Services Agreement (the “Program Agreement”) with PDS, TPL, and Alliacense Limited, LLC (“Alliacense”, an affiliate of TPL), and an Agreement (the “TPL Agreement”) with TPL. Pursuant to the Program Agreement, PDS engaged Alliacense to negotiate MMP portfolio licenses and to pursue claims against violators of the MMP portfolio on behalf of PDS, TPL, and the Company. The Program Agreement continues through the useful life of the MMP portfolio patents. Pursuant to the TPL Agreement, we and TPL agreed to certain allocations of obligations in connection with the engagement of Alliacense."

"On July 17, 2012, we entered into an Agreement with PDS and TPL whereby we agreed to certain additional allocations of obligations relating to the Program Agreement." (***IMO, you will notice that Alliacense is specifically not a named party to this agreement, and this "agreement" is NOT identified as the Licensing Agreement, therefor Alliacense retains the powers granted to it in the July 11, 2012 "Licensing Program Services Agreement")

Pursuant to the Program Agreement, PDS has committed to advance Alliacense a quarterly amount of $500,000 for supporting efforts to secure licensing agreements on behalf of PDS. These advances replace the quarterly amounts previously paid to TPL pursuant to the Commercialization Agreement.....

Share
New Message
Please login to post a reply